Biological Lattice Industries (BLI) develops an integrated biofabrication platform combining hardware and software to simplify biomaterials design, fabrication, and testing. Its core products are BioLoom™, a multi-tool extrusion-based 3D bioprinter with Active Environmental Control for reproducibility and GMP alignment, and Loominus Studio™, a unified software platform that automates and integrates biofabrication workflows. BLI says the platform targets both academic and commercial labs and has already deployed systems to leading academic labs through an early-adopters program. The company positions itself to accelerate commercialization of biomaterials, resorbable medical devices, and advanced 3D cell-culture systems. BLI was founded in 2021 and operates as a US startup with R&D operations in Greece. The company recently closed a $1.8 million pre-seed financing to accelerate product development and market availability.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2024